HK1259409A1 - 酪蛋白激酶1δ在乳腺癌中的治疗靶向 - Google Patents

酪蛋白激酶1δ在乳腺癌中的治疗靶向 Download PDF

Info

Publication number
HK1259409A1
HK1259409A1 HK19101778.5A HK19101778A HK1259409A1 HK 1259409 A1 HK1259409 A1 HK 1259409A1 HK 19101778 A HK19101778 A HK 19101778A HK 1259409 A1 HK1259409 A1 HK 1259409A1
Authority
HK
Hong Kong
Prior art keywords
cancer
breast cancer
breast
delta
casein kinase
Prior art date
Application number
HK19101778.5A
Other languages
English (en)
Chinese (zh)
Inventor
William R. Roush
Derek R. DUCKETT
John L. CLEVELAND
Laura H. ROSENBERG
Original Assignee
The Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Scripps Research Institute filed Critical The Scripps Research Institute
Publication of HK1259409A1 publication Critical patent/HK1259409A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK19101778.5A 2015-10-13 2016-10-05 酪蛋白激酶1δ在乳腺癌中的治疗靶向 HK1259409A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562240689P 2015-10-13 2015-10-13
US62/240,689 2015-10-13
PCT/US2016/055436 WO2017066055A1 (en) 2015-10-13 2016-10-05 THERAPEUTIC TARGETING OF CASEIN KINASE 1δ IN BREAST CANCER

Publications (1)

Publication Number Publication Date
HK1259409A1 true HK1259409A1 (zh) 2019-11-29

Family

ID=58517824

Family Applications (1)

Application Number Title Priority Date Filing Date
HK19101778.5A HK1259409A1 (zh) 2015-10-13 2016-10-05 酪蛋白激酶1δ在乳腺癌中的治疗靶向

Country Status (8)

Country Link
US (2) US10603322B2 (enExample)
EP (1) EP3362452A4 (enExample)
JP (1) JP2018538241A (enExample)
CN (1) CN108431006A (enExample)
AU (1) AU2016338639A1 (enExample)
CA (1) CA3001903A1 (enExample)
HK (1) HK1259409A1 (enExample)
WO (1) WO2017066055A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200078387A1 (en) * 2016-12-16 2020-03-12 The Johns Hopkins University Chemical inhibitors against kinases to block telomere elongation in cancer
WO2019145386A1 (en) 2018-01-26 2019-08-01 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating csnk1d expression
WO2019217421A1 (en) 2018-05-08 2019-11-14 The Scripps Research Institute Small molecule inhibitors of cdk12/cdk13
BR112021003093A2 (pt) * 2018-08-22 2021-05-11 Merck Patent Gmbh tratamento de câncer de mama triplo negativo que visa a inibição de tgf-beta

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493464B2 (en) * 2012-02-29 2016-11-15 The Scripps Research Institute Wee1 degradation inhibitors
CN105188704B (zh) * 2013-01-16 2017-09-19 西格诺药品有限公司 被取代的吡咯并嘧啶化合物、其组合物和使用其的治疗方法

Also Published As

Publication number Publication date
US20200163972A1 (en) 2020-05-28
CN108431006A (zh) 2018-08-21
EP3362452A1 (en) 2018-08-22
US20180311252A1 (en) 2018-11-01
JP2018538241A (ja) 2018-12-27
EP3362452A4 (en) 2019-06-12
AU2016338639A1 (en) 2018-05-10
US10603322B2 (en) 2020-03-31
WO2017066055A1 (en) 2017-04-20
CA3001903A1 (en) 2017-04-20

Similar Documents

Publication Publication Date Title
PH12019501959A1 (en) Therapeutic rna
IL281256A (en) Combined treatment for the treatment of triple-negative breast cancer
MX2019000200A (es) Agentes antiproliferativos basados en pirimidina.
MX2020010496A (es) Inhibidores de desmetilasa-1 especifica de lisina.
PH12016502354A1 (en) Pharmaceutical composition
MX2015007185A (es) Uso de eribulina en el tratamiento de cancer de pecho.
MX381597B (es) Inhibidores demetilasa-1 específica de lisina.
MX376632B (es) Inhibidores de demetilasa-1 especifica de lisina.
MX376207B (es) Inhibidores de demetilasa-1 especifica de lisina.
TN2017000032A1 (en) Protein kinase c inhibitors and methods of their use
AU2018380132A8 (en) Tubulin inhibitors
MX391865B (es) Inhibidores de demetilasa-1 especifica de lisina.
MX2020003126A (es) Derivados de iminopirimidina ciclicos como inhibidores de cinasa.
NZ726365A (en) Combinations for treating cancers
EA201790502A1 (ru) Ингибиторы гистоновых диметилаз
SG11202100947SA (en) Treatment of metastatic brain tumor by administration of antibody-drug conjugate
HK1259409A1 (zh) 酪蛋白激酶1δ在乳腺癌中的治疗靶向
PH12020551543A1 (en) Therapeutic modulators of the reverse mode of atp synthase
MX2017015424A (es) Nanoparticulas para su uso como vacuna terapeutica.
IL290373A (en) Combinations of tgfb inhibitors and cdk inhibitors for the treatment of breast cancer
PH12018502360A1 (en) 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers
EA201892562A1 (ru) Способы и материалы для определения стадий и лечения рака кожи
PH12012500296A1 (en) Anti-angiogenesis therapy for the treatment of previously treated breast cancer
MX2021002884A (es) Terapia de combinacion para el tratamiento de cancer de prostata.
NZ742470A (en) Combination therapy for cancer